doi:10.1093/brain/awh682Brain (2005) Page 1 of 18
Molecular and cellular mechanisms of
pharmacoresistance in epilepsy
Stefan Remy and Heinz Beck
Department of Epileptology, University of Bonn Medical Center, Bonn, Germany
Correspondence to: Heinz Beck, MD, Department of Epileptology, University of Bonn Medical Center,
Sigmund-Freud-Strasse 25, 53105 Bonn, Germany
Epilepsy is a common and devastating neurological disorder. In many patients with epilepsy, seizures are
well-controlled with currently available anti-epileptic drugs (AEDs), but a substantial (?30%) proportion of
patients continue to have seizures despite carefully optimized drug treatment. Two concepts have been put
forward to explain the development of pharmacoresistance. The transporter hypothesis contends that
the expression or function of multidrug transporters in the brain is augmented, leading to impaired access
of AEDs to CNS targets. The target hypothesis holds that epilepsy-related changes in the properties of the
drug targets themselves may result in reduced drug sensitivity. Recent studies have started to dissect the
molecular underpinnings of both transporter- and target-mediated mechanisms of pharmacoresistance in
human and experimental epilepsy. An emerging understanding of these underlying molecular and cellular
mechanisms is likely to provide important impetus for the development of new pharmacological treatment
Keywords: epilepsy; pharmacoresistance; anti-epileptic drugs; multidrug transporter; ion channel
Abbreviations: AED = anti-epileptic drug; ABC = adenosine triphosphate-binding cassette; PGP = P-glycoprotein
Received April 13, 2005. Revised July 22, 2005. Accepted October 13, 2005
Introduction to the clinical problem of
pharmacoresistance in epilepsy
Epilepsy is a common and devastating neurological disorder.
In many patients with epilepsy, seizures are well-controlled
with currently available anti-epileptic
However, seizures persist in a considerable proportion of
these patients. The exact fraction of epilepsy patients who
are considered refractory varies in the literature, mostly
because the criteria for classification as pharmacoresistant
have varied. Nevertheless, a substantial proportion (?30%)
line AEDs, despite administration in an optimally monitored
regimen (Regesta and Tanganelli, 1999). The fraction of
patients who are pharmacoresistant appears to correlate with
certain features of the epileptic condition, such as a high
seizure frequency or febrile seizures prior to treatment, early
onset of seizures or the presence of certain types of structural
brain lesions. In addition, pharmacoresistance occurs fre-
quently in patients with partial seizures (Aicardi and
Shorvon, 1997; Regesta and Tanganelli, 1999 for a more
complete discussion of clinical aspects of pharmacoresist-
ance). Despite the obvious clinical relevance of uncontrolled
seizures in a large fraction of epilepsy patients, the cellular
basis of pharmacoresistance has so far remained elusive. The
availability of tissue from epilepsy patients undergoing
surgery for focal epilepsies, primarily temporal lobe epilepsy,
has allowed to address some of the mechanisms underlying
pharmacoresistance of focal epilepsies. The mechanisms
underlying the development of resistance in certain forms
of generalized epilepsies are still enigmatic.
Introduction to the cellular candidate
mechanisms of pharmacoresistance
Which key mechanisms govern efficacy of CNS drugs? Firstly,
in the presence of adequate, carefully monitored serum AED
levels, drugs have to traverse the blood–brain barrier (BBB).
Subsequently, CNS activity of AEDs is determined by a
#The Author (2005). Published by Oxford University Press on behalf of the Guarantors of Brain. All rights reserved. For Permissions, please email: firstname.lastname@example.org
Brain Advance Access published November 29, 2005
multitude of factors, including physical properties, such as
lipophilicity, that affect their distribution in different
compartments within the CNS. Consequently, one scenario
to explain pharmacoresistance could be that sufficient intra-
presence of adequate AED serum levels. Such a phenomenon
could arise via an enhanced function of multidrug transport-
ers that control intraparenchymal AED concentrations
(transporter hypothesis of pharmacoresistance, Kwan and
Following permeation into the CNS parenchyma, drugs
have to bind to one or more target molecules to exert their
desired action. Thus, pharmacoresistance may also be caused
by a modification of one or more drug target molecules
(seeTable 1).Thesemodifications would thencause areduced
efficacy of a given AED at the target. This concept has been
collectively termed the target hypothesis of pharmacoresist-
ance (Fig. 1).
Modification in drug targets as basis
The cellular mechanisms of AEDs have been examined to
some extent in normal brain tissue, or ion channels and
receptors in expression systems. These data are summarized
qualitatively in Table 2. Many of these drug targets are altered
on a molecular level in epilepsy. In the following sections, we
will attempt to summarize briefly the known mechanisms of
AEDs on ion channels. We will then focus on emerging
experimental evidence supporting a loss of AED efficacy at
selected targets, and discuss the possible molecular basis of
Changes in molecular drug targets
Voltage-gated Na+currents are ubiquitously expressed in
excitable cells (Fig. 2A, Goldin, 1999; Goldin et al., 2002),
and appear to be targets for multiple first-line AEDs. Upon
depolarization of the membrane, the channels activate and
responsible for the rising phase of the action potential,
and—in some cells—a slowly-inactivating ‘persistent’ current
(INaP, see Fig. 2C). Both current components represent major
targets of several first-line AEDs including carbamazepine,
phenytoin (PHT), lamotrigine and valproate (Ragsdale and
Avoli, 1998; Catterall, 1999; Ko ¨hling, 2002, see also Table 2).
Most AEDs block Na+channels in their resting state (tonic
block) at hyperpolarized membrane potentials (Ragsdale and
Avoli, 1998), with a voltage-dependent enhancement of the
block towards more depolarizing potentials. This voltage-
dependent inhibition is associated with a shift of the steady-
Importantly, blocking effects are activity- or use-dependent,
i.e. blocking effects are enhanced when neurons are repetit-
ively depolarized at higher frequencies (Fig. 2E and F). This
fast Na+channel inactivation (Ragsdale and Avoli, 1998;
Catterall, 1999). It has been suggested that use-dependent
blocking effects are important because they result in a pref-
erential block of INaTduring prolonged high-frequency neur-
onal activity, such as that occurring during seizures.
Several lines of evidence so far have indicated that reduced
efficacy in inhibiting INaTmay be a candidate mechanism of
Table 1 Changes in known AED targets or drug efflux transporters in experimental epilepsy models and
human epileptic tissue
Target ModificationCell type Human
Voltage-gated sodium channels Downregulation of accessory subunits
Altered alpha subunit expression,
induction of neonatal isoforms
Dentate granule cells
CA1 pyramidal neurons
CA1 pyramidal neurons
CA3 pyramidal neurons
Dentate granule cells
CA1 pyramidal neurons
Entorhinal cortex layer 3 neurons
Voltage-gated calcium channels
Increased expression of T-type channels
Loss of dendritic IH
GABAAreceptors: decrease of a1
increase of a4subunits
Dentate granule cells Yes
Capillary endothelial cells
Capillary endothelial cells
MVP (major vault protein)Overexpression No
Page 2 of 18 Brain (2005) S. Remy and H. Beck
pharmacoresistance to some AEDs. Firstly, in CA1 neurons,
the effects of carbamazepine on the steady-state inactivation
properties of INaTwere transiently reduced in the kindling
model of epilepsy (Vreugdenhil and Wadman, 1999b). In
contrast to these comparatively modest and transient effects,
a complete and long-lasting loss of use-dependent blocking
effects of carbamazepine was found in the pilocarpine model
of epilepsy in hippocampal dentate granule cells, as well as in
epilepsy patients with carbamazepine-resistant temporal lobe
epilepsy (Remy et al., 2003a). This dramatic loss of a major
mechanism of action of carbamazepine did not extend to
other AEDs known to affect INaT. Following pilocarpine-
induced status epilepticus, the use-dependent effects of
PHT were reduced, but not completely lost, while the effects
of lamotrigine were completely unchanged (Remy et al.,
2003b). Although the mechanisms of INaTinhibition induced
by valproate are still controversial (Xie et al., 2001); but see
(Vreugdenhil et al., 1998; Vreugdenhil and Wadman, 1999b),
this substance exhibits potent voltage-dependent blocking
effects in various preparations (Fohlmeister et al., 1984;
Zona and Avoli, 1990; Vreugdenhil and Wadman, 1999b;
Ko ¨hling, 2002). Notably, in tissue obtained from pharma-
coresistant patients and in experimental epilepsy no differ-
(Vreugdenhil et al., 1998; Vreugdenhil and Wadman, 1999b;
Remy et al., 2003b). Collectively, these results suggest that
epileptogenesis causes changes in the properties of INaT
that may differ depending on the cell type examined
Fig. 1 In the pharmacoresistant patient the drug faces a modified target, with which it interacts less effectively (A, panel b). Putative
candidate mechanisms resulting in target modifications are seizure-induced changes in transcription or alternative splicing of ion channel
subunits, altered post-translational modification of the protein and/or phosphorylation by protein kinases. A second emerging concept to
explain pharmacoresistance contends that increased expression or function of multidrug transporter proteins decreases availability of the
AED at its target (B, panel b versus B, panel a). In the non-epileptic brain, drug transporter molecules are predominantly expressed in
endothelial cells, and in some cases astrocytes (see text), and appear to regulate intraparenchymal AED concentrations by extruding certain
AEDs over the blood–brain or blood–CSF barrier (indicated by arrows in B, panel a). An upregulation of various drug transporter
molecules has been described in human epilepsy as well as in experimental epilepsy models (B, panel b). This upregulation may decrease the
effective concentration of AEDs at their targets. In addition, in the setting of an epileptic brain, an ectopic expression of certain drug
transporter genes has been observed in astrocytes and in neurons. It remains unresolved whether such transporters control access of
AEDs to intracellular targets (indicated by the absence of an arrow in the neuron in B, panel b).
Pharmacoresistance in epilepsyBrain (2005)Page 3 of 18
Table 2 Summary of AED targets
Voltage-dependent ion channels
(Willow et al.,
1985; Schwarz and
Ragsdale et al.,
1991; Kuo, 1998;
Segal and Douglas,
1997; Lampl et al.,
(Stefani et al.,
Schumacher et al.,
(Todorovic et al.,
et al., 2001)
(Willow et al.,
1985; Schwarz and
Grigat, 1989; Kuo,
et al., 1999;
(Schumacher et al.,
(McLean et al.,
et al., 1994)
(Schmutz et al.,
1994; Stefani et al.,
(Xie et al., 2001;
Xie et al., 1995;
Zona and Avoli,
1997; Remy et al.,
2003b; Kuo, 1998)
(Spadoni et al.,
(Stefani et al.,
et al., 1996)
(Huang et al.,
2004; Zona et al.,
(Poolos et al.,
Zona and Avoli,
et al., 1998;
(Taverna et al.,
1998), but see
et al., 2004)
(Taverna et al.,
(Lo ¨scher, 1989)
(Gebhardt et al.,
(Main et al., 2000),
(Tatulian et al.,
2001; Yue and
(Suzuki et al.,
Page 4 of 18 Brain (2005)S. Remy and H. Beck
(Taglialatela et al.,
(Stefani et al.,
(Rho et al., 1997)
et al., 1995; White
et al., 1995; Kuo
et al., 2004)
(Zona et al., 1997;
Taverna et al.,
et al., 2000)
(Taverna et al.,
(Zhang et al.,
(Herrero et al.,
Gordey et al.,
(Gibbs, III et al.,
2000; Gryder and
(Leresche et al.,
(Coulter et al.,
and Lingle, 1998;
Gomora et al.,
2001), but see
(Leresche et al.,
(Leresche et al.,
No effect: (Zona
et al., 2001)
et al., 2004)
(Lukyanetz et al.,
effect: (Zona et al.,
(Madeja et al.,
(Alden and Garcia,
2001), but see
(Schumacher et al.,
(Freiman et al.,
(Surges et al.,
(McClelland et al.,
et al., 1993)
(Twyman et al.,
(Study and Barker,
1994; Eghbali et al.,
et al., 1999)
(Jolkkonen et al.,
1992; Lo ¨scher and
1994; Wu et al.,
(Fink-Jensen et al.,
and Ga ¨hwiler,
Pharmacoresistance in epilepsyBrain (2005) Page 5 of 18
(i.e. dentate granule cells versus CA1 neurons), and according
to the epilepsy model studied. Changes in INaTmay then
dramatically affect sensitivity to some, but not all, AEDs.
Block of INaPmay also be a crucially important mechanism
of AED action. Pharmacological augmentation of INaPcauses
an increased propensity of individual neurons to generate
burst discharges (Su et al., 2001), and several mutations
that give rise to increased INaPcause epilepsy in mice or
humans (Kearney et al., 2001; Lossin et al., 2002; Rhodes
et al., 2004; Spampanato et al., 2004). INaP is efficiently
Fig. 2 Expression, functional properties and AED pharmacology of voltage-gated sodium channels. The Na+channel alpha subunits
NaV1.1–NaV1.9 are widely distributed in excitable cells and exhibit a tissue-specific expression (A). Upon depolarization the channels
activate and give rise to a rapidly inactivating ‘transient’ inward Na+current (INaT, B), responsible for the rising phase of the action potential.
In addition, in some cells a slowly-inactivating ‘persistent’ current has been described (INaP, C). Slow voltage-ramp commands allow to
describe the voltage-dependent properties of this current component in isolation. The persistent Na+current contributes to spike after-
depolarizations in some neurons and plays a role in the generation and maintenance of subthreshold membrane oscillations. Na+channels
are the main targets for a subset of AEDs including carbamazepine, PHT and lamotrigine. The drugs acting on INaTchannels display two
predominant mechanisms of action: 1. Voltage-dependent inhibition, associated with a shift of the steady-state inactivation curve in a
hyperpolarized direction. This shift decreases the availability of the Na+channel during an action potential and, therefore, reduces the
excitability of the cell (D). 2. Activity- or use-dependent blocking effects, i.e. blocking effects are enhanced when neurons are repetitively
depolarized at higher frequencies (E and F). This results in a highly efficient block of INaTpreferentially during prolonged high-frequency
neuronal activity, such as that occurring during seizures.
Page 6 of 18Brain (2005) S. Remy and H. Beck
blocked by many AEDs, frequently at a concentration range
lower than that observed for INaT(Ko ¨hling, 2002). In native
well as losigamone (Chao and Alzheimer, 1995; Lampl et al.,
data). Despite the potential importance of INaPin the regu-
epileptogenesis have so far not been described.
What mechanisms can account for an altered sensitivity of
Na+channels in epileptic tissue? One possibility may be that
the subunit composition of these channels is altered, such
that the expression of AED-insensitive subunits or subunit
combinations is promoted. Indeed, numerous changes in Na+
channel subunit expression have been observed in both
human and experimental epilepsy (Bartolomei et al., 1997;
Aronica et al., 2001; Whitaker et al., 2001; Ellerkmann et al.,
2003). In this respect, the downregulation of accessory Na+
channel b1and b2subunits following experimentally induced
status epilepticus appears to be a consistent finding (Gastaldi
et al., 1998; Ellerkmann et al., 2003). In addition to changes in
mRNA levels, altered alternative splicing of pore-forming
subunit mRNAs has also been observed (Gastaldi et al.,
1997; Aronica et al., 2001). A recent, very interesting study
underscores the potential importance of the b1subunit in the
development of pharmacoresistance. In the paper by Lucas
et al. (2005), the pharmacology of Na+channels containing a
mutant b1subunit causing the epilepsy syndrome generalized
epilepsy with febrile seizures plus was examined. Surprisingly,
Na+channels containing mutant b1subunits displayed a dra-
matic and selective loss of use-dependent block by the AED
PHT, that was very similar to the effects observed in chronic
experimental epilepsy for PHT and carbamazepine (Remy
et al., 2003a, b). These results collectively suggest that changes
in accessory subunits might be promising candidates for
further investigation as a molecular correlate of the AED-
insensitive sodium channel. They are also intriguing because
they suggest that use-dependent effects on Na+channels
require some form of interaction with b1subunits, whereas
this may not be the case for tonic block of Na+channels.
It is at present unclear why use-dependent block by
carbamazepine and PHT is lost or reduced, whereas use-
dependent block by lamotrigine remains intact in experi-
mental epilepsy. This is an intriguing question because it
has been suggested that all three drugs bind to the same
site on Na+channels in CA1 neurons based on coapplication
experiments (Kuo et al., 1998). The mutual exclusivity among
the binding of drugs simultaneously applied to a channel may
however result from either an allosteric mechanism or from
direct competition of the drugs at a single binding site. Even
though a single binding site appears to provide the most
parsimonious explanation for these results, it is quite
conceivable that allosteric interactions between different
binding sites may also exist. This would provide a basis for
the AED-selective loss of sensitivity observed in chronic
Other types of voltage-gated channels
Other types of voltage-gated channels have also been screened
as potential drug targets. In many cases, effects of AEDs on
specific ion channel subunits or ion channels in native neur-
ons or expression systems have been described (see Table 2).
Ca2+channels can be subdivided into two groups: high-
threshold Ca2+currents, and a group of low-threshold
currents (also termed T-type Ca2+currents, Ertel et al.,
2000). A number of AEDs has been shown to inhibit high
threshold Ca2+channels in native neurons at high therapeutic
concentrations (Stefani et al., 1997b, 1998; Schumacher et al.,
1998; see Table 2). Additionally, the AED gabapentin has been
shown to exhibit strong and specific binding to the accessory
a2d subunit (Gee et al., 1996). It has been proposed that
this effect underlies inhibition of presynaptically expressed
high-threshold Ca2+channels by gabapentin, which causes
a reduction in neurotransmitter release (Fink et al., 2000;
see Table 2). Some AEDs potently inhibit low-threshold
T-typeCa2+channels, which are notexpressedpresynaptically
(Yaari et al., 1987; Coulter et al., 1989; Gomora et al., 2001;
see Table 2). The effects of AEDs on the three T-type Ca2+
channel subunits, as well as in native neurons, are diverse
(cf. Todorovic and Lingle, 1998; Todorovic et al., 2000;
Lacinova, 2004). T-type channels are critically important in
controlling the excitability of the postsynaptic compartment
of neurons (Huguenard, 1996), both in normal and epileptic
neurons. For instance, aberrant bursting is seen in CA1 hip-
pocampal neurons from epileptic animals (Sanabria et al.,
2001) that is mediated by increased expression of T-type
Ca2+channels (Su et al., 2002). Additionally, T-type Ca2+
channels in thalamic neurons have been implicated in the
generation of spike-wave discharges in absence epilepsy
(Huguenard, 2002 and references therein). Consequently,
inhibition of burst discharges in thalamic neurons is thought
to contribute tothe anti-epileptic effects of antiabsenceAEDs.
It is so far unknown if the sensitivity of either presynaptic or
post-synaptic Ca2+channels to AEDs changes during epilep-
togenesis. The same applies to other voltage-gated ion chan-
nels such as K+channels (see Table 2).
H-currents (IH) are mixed cationic currents that are activ-
ated by hyperpolarization and deactivated following repolar-
ization of the membrane. IHhas multiple functional roles; for
instance, it mediates some forms of pacemaker activity in
heart and brain, it regulates membrane resistance and dend-
ritic integration and stabilizes the level of the resting potential
(reviewed, Robinson and Siegelbaum, 2003). An interesting
predominantly located in dendrites, rather than the soma
of neurons (Poolos et al., 2002). Interestingly, dendritic
H-currents are potently enhanced by the AEDs lamotrigine
and gabapentin at clinically relevant concentrations (Poolos
et al., 2002; Surges et al., 2003, see Table 2), resulting in
IH-mediated inhibitory effects on action potential firing by
selectively reducing the excitability of the apical dendrites
(Poolos et al., 2002). Cell-type specific changes in IHhave
Pharmacoresistance in epilepsyBrain (2005)Page 7 of 18
been described in models of epilepsy (Chen et al., 2001),
including a dramatic loss of dendritic IHin entorhinal cortex
neurons (Shah et al., 2004). The importance of this change for
pharmacoresistance to lamotrigine has not been directly
addressed, but it is conceivable that a sufficiently large reduc-
tion of these channels could constitute a de facto loss of a
major drug target for lamotrigine in this subregion.
Neurotransmitter systems: GABA
GABA is the predominant inhibitory neurotransmitter in the
adult brain and plays a critical role in the regulation of excit-
ability of neuronal networks (Mody and Pearce, 2004). GABA
binding to ionotropic GABAAreceptors causes opening of the
receptor ionophore, which is permeable to Cl?and—to a
lesser extent—to HCO3. In the presence of a normal adult
transmembraneous Cl?gradient, this results in expression of
an inhibitory post-synaptic current that hyperpolarizes the
post-synaptic neuronal membrane. Direct modulators of
GABAAreceptors include benzodiazepines and barbiturates.
Benzodiazepines increase GABA affinity of the receptor com-
plex and may augment their Cl?conductance via allosteric
modulation (Twyman et al., 1989a; Rudolph et al., 1999,
2001). Substances that interact with the GABA system in a
more indirect way affect the handling and metabolism of
synaptically released GABA.
GABA) is a GABA analogue that inhibits one of the main
enzymes controlling GABA concentrations in the brain,
GABA transaminase. Consequently, application of vigabatrin
causes large elevations in brain GABA levels. The AED tiaga-
bine inhibits the high-affinity GABA transporter GAT1 that
normally terminates synaptic action of GABA via rapid
uptake. So far, available evidence indicates that neither the
efficacy of GABA uptake, nor its sensitivity to tiagabine is
altered in chronic experimental epilepsy (Frahm et al., 2003).
Regarding GABAAreceptor agonists, reduced activity of
such substances has been described in a chronic model of
epilepsy. In the pilocarpine model of epilepsy, GABAArecept-
ors of dentate granule cells show a reduced sensitivity to drugs
acting on the benzodiazepine receptor site 1. While augmen-
tation of GABA-evoked currents by the broad-spectrum
animals, augmentation by the benzodiazepine site 1-selective
agonist zolpidem was strongly decreased (Gibbs et al., 1997;
Brooks-Kayal et al., 1998; Cohen et al., 2003). In CA1 pyr-
amidal cells, the effects of clonazepam were dramatically
reduced in chronically epileptic animals (81% reduction rel-
ative to control, (Gibbs et al., 1997). This suggests that the
same might also apply to clinically employed benzo-
What is the molecular mechanism of this change in GABAA
receptor pharmacosensitivity? An enormous diversity of
GABAAreceptors has been reported in the CNS, reflecting
the fact that in each receptor at least three different sub-
units are present, which derive from one of eight structur-
ally distinct and genetically distinct families (Costa, 1998;
Sperk et al., 2004). Combined molecular and functional
studies indicate that a transcriptionally mediated switch in
the alpha subunit composition of GABAAreceptors occurs
in epileptic animals, in particular a decrease of a1subunits
and an increase of a4subunits (Brooks-Kayal et al., 1998).
These findings correlate well with the observed changes in
benzodiazepine receptor pharmacology.
Neurotransmitter systems: glutamate
Despite the undoubted importance of altered glutamate-
mediated excitatory neurotransmission in chronic experi-
mental (Mody and Heinemann, 1987; Martin et al., 1992;
Kohr et al., 1993) and human epilepsy (Isokawa and
Levesque, 1991), few substances acting on this system have
been developed to clinical use so far. Felbamate exerts com-
plex effects on the NMDA receptor (Kuo et al., 2004), some of
which may be mediated via the modulatory glycine binding
site (White et al., 1995). Some of the effects of felbamate have
been shown to be affected by NMDA receptor subunit com-
position (Kleckner et al., 1999; Harty and Rogawski, 2000).
AEDs acting on AMPA receptors are also scarce, some
drugs currently in clinical trials inhibit AMPA receptors
(talampanel, see Chappell et al., 2002). Likewise, topiramate
has been shown to reduce excitatory synaptictransmission via
an inhibition of AMPA receptors (Qian and Noebels, 2003).
Altered cellular expression of glutamate receptors in
epilepsy should be considered in future development of com-
pounds acting on these receptors. Given the paucity of estab-
lished AEDs acting on individual glutamate receptors,
however, we will abstain from an in depth discussion of
these changes here.
Role of changes in drug targets in the
setting of a chronically epileptic brain
The specific changes in drug targets described above are an
ant to realize, however, that not only changes in drug targets
themselves, but also changes in other molecules that affect
their function may have important consequences for AED
efficacy. This idea is exemplified by recent findings regarding
the role of GABA in epilepsy. GABA may on occasion act as
an excitatory neurotransmitter in the immature brain. A
depolarizing action of GABAA receptor activation arises
because of an altered chloride homeostasis, resulting in a
changed chloride gradient across the neuronal membrane.
The altered chloride reversal potential then results in a net
outward flux of Cl?through the GABAAreceptor ionophore,
causing depolarization of the neuron (Mody and Pearce,
2004). Interestingly, in addition to the developing brain,
depolarizing GABA responses appear to be a feature of
some neurons in the epileptic brain (Cohen et al.,
2002; Wozny et al., 2003). Augmenting such depolarizing
GABA-mediated potentials by application of GABA agonists
is likely to facilitate action potential generation to excitatory
Page 8 of 18Brain (2005) S. Remy and H. Beck
neuronal excitability instead of decreasing it. Whether depol-
arizing GABA responses really play a role in pharma-
coresistance to GABAmimetic drugs remains to be seen.
These considerations do, however, illustrate the need to con-
sider changes in drug targets within the more general setting
of a chronically epileptic brain.
Molecular mechanisms underlying altered
So far, most of the mechanisms implicated in altered AED
targets are changes in the transcription of ion channel sub-
units. Seizures appear to cause a highly coordinated change in
transcription of certain groups of ion channel subunits, both
in rat models of epilepsy (Brooks-Kayal et al., 1998) and in
human epilepsy patients (Brooks-Kayal et al., 1999; Bender
et al., 2003). This seizure-induced transcriptional plasticity
appears to be differentially regulated in different neuron types
(cf. Bender et al., 2003; Shah et al., 2004). These transcrip-
tional changes most probably affect both the density of ion
channels in the neuronal membrane, as well as the subunit
stochiometry of multisubunit channel complexes (Brooks-
Kayal et al., 1998). In addition to transcriptional mechanisms,
seizure activity may also evoke multiple post-translational
modifications of ion channel proteins, such as altered protein
transport and targeting, phosphorylation or glycosylation
(Bernard et al., 2004). Indeed, increased phosphorylation
of INaby protein kinase C has been shown to affect respons-
iveness to the AED topiramate in one study (Curia et al.,
2004). It is quite possible that other post-transcriptional
modifications of ion channel proteins induced by seizures
may profoundly affect their drug sensitivity. How seizures
may modify the pharmacosensitivity of AED targets is
summarized schematically in Fig. 3.
Relationship of molecular changes in AED
sensitivity to pharmacoresistance
observed in vivo
How is the loss of AED sensitivity on the level of an ion
channel such as INaTrelated to pharmacoresistance observed
in human epilepsy patients or intact animals? In epilepsy
patients, properties of INaTseemed to differ when patients
are separated into two groups, one resistant to carbamazepine
anda smaller one responsivetocarbamazepine.In theformer,
the use-dependent block of INaTproved to be abolished,
similar to the findings in the pilocarpine model of epilepsy.
use-dependent effects of carbamazepine on INaT. Thus, the
sensitivity to carbamazepine on a cellular level appeared to
correlate with the clinical responsiveness to the same drug.
Firstly, the number of patients for which both clinical and
in vitro data could be obtained is still limited, particularly
when considering the group of pharmacoresponsive epilepsy
patients (Remy et al., 2003a). Secondly, patients who are
resistant to carbamazepine very frequently are resistant also
to other AEDs (Kwan and Brodie, 2000). However, available
data indicate that altered sensitivity of Na+channels may not
be able to account for altered efficacy of other AEDs such as
valproic acid or lamotrigine (Remy et al., 2003b). This finding
may indicate that resistance to AEDs in epilepsy patients is a
complex phenomenon that possibly relies on multiple mech-
yield candidate gene polymorphisms that may be associated
with AED sensitivity (Tate et al., 2005).
The correlation of target pharmacosensitivity and sensitiv-
ity to AEDs in vivo in experimental models of epilepsy is quite
unclear. The pilocarpine model of epilepsy has been
frequently used to study changes in pharmacosensitivity of
drug targets. Leite and Cavalheiro (1995) have provided some
evidence that high doses of common AEDs such as car-
bamazepine, PHT and valproate reduce the spontaneous
seizure frequency in these animals. This is in apparent con-
tradiction to the finding that Na+channels in the same model
are resistant to carbamazepine. It is possible that this may be
due to the high doses of AEDs used, or alternatively to dif-
ferences in the rat strains and/or pilocarpine protocols used.
Furthermore, it is likely that some groups responsive and
resistant to AED may exist in chronic epilepsy models
(Lo ¨scher et al., 1998; Nissinen and Pitka ¨nen, 2000). Ideally,
these questions could, therefore, be resolved by first examin-
ing pharmacosensitivity in intact animals, and subsequently
comparing these in vivo results to the cellular effects of AEDs
in the same individuals. So far, this important approach has
only been implemented in few experiments (Jeub et al., 2002).
For these experiments, kindled rats were used that could be
separated into two groups based on their responsiveness to
compared to a group of rats that were not, no difference in
PHT sensitivity of INaTemerged. It should be noted, however,
that PHT effects on the recovery from inactivation and use-
dependent block, where the most dramatic effects were seen in
the pilocarpine model of epilepsy, were not examined in this
groups with differential pharmacosensitivity can be defined
represent a promising avenue to study mechanisms of phar-
macoresistance (Nissinen and Pitka ¨nen, 2000). It remains to
be seen how far such animal models mirror mechanisms of
pharmacoresistance in human epilepsy patients.
Modification in multidrug transporters
as basis for pharmacoresistance
Overview of multidrug transporter
molecules expressed in the brain
The second main emerging concept to explain pharma-
coresistance contends that increased expression or function
of multidrug transporter proteins decreases the effective
concentration of AEDs at their targets (see Fig. 1B). Intense
Pharmacoresistance in epilepsyBrain (2005)Page 9 of 18
interest has been focused on understanding the molecular
basis of multidrug transport in the brain in recent years,
primarily because of their potential importance in mediating
resistance to anticancer drugs. This effort has led to the dis-
function as drug efflux pumps. These genes are highly con-
served and the vast majority belongs to the superfamily of
adenosine triphosphate-binding cassette (ABC) proteins. A
large number of human genes belonging to this superfamily
have been identified, which have been systematically classified
into seven subfamilies [ABCA, ABCB, ABCC, ABCD, ABCE
ABCF and ABCG (Dean et al., 2001)]. Most of these genes
encode ATP-driven pumps that are able to transport a wide
range of substrates.
Studies addressing the role of multidrug transporters in
the development of pharmacoresistant epilepsy have hitherto
been focused mainly on a subset of these transporters. MDR1
(belonging to the ABCB subfamily, systematic nomenclature
ABCB1) encodes P-glycoprotein (PGP, Silverman et al.,
1991; Ueda et al., 1993), which transports a wide range of
lipophilic substances across cell membranes. A further family
of genes [multidrug-resistance associated proteins or MRPs,
transports a range of substances partially overlapping with
those transported by PGP. Most of the proteins encoded
by these genes (i.e. MRP1 to 6 and PGP) are expressed in
endothelial cells of the blood–brain or blood–CSF barrier
(Schinkel et al., 1996; Huai-Yun et al., 1998; Rao et al.,
1999; Zhang et al., 1999). In addition, MRP1 and one of
the two rodent isoforms of PGP are present in astrocytes
(Pardridge et al., 1997; Regina et al., 1998; Golden and
Pardridge, 1999; Decleves et al., 2000). The functional role
of this expression is currently a matter of debate (Golden and
Altered expression of multidrug
transporters in human and experimental
epilepsy, and consequences for
intraparenchymal AED concentrations
Several lines of evidence indicate a role of multidrug trans-
porters in the development of resistance to AEDs, which are
set out in more detail as follows. Firstly, drug transporters
transport some AEDsin isolated cell systems(Batrakova et al.,
1999; Marchi et al., 2004). Secondly, drug transporters appear
to regulate intraparenchymal drug concentrations in vivo in
many cases. Mice or rats lacking certain drug transporters
display increased accumulation of AEDs (Schinkel et al.,
1996, 1997; Rizzi et al., 2002; Potschka et al., 2003b, but see
Sills et al., 2002; see Table 3). It should be noted that inter-
pretation of data from such animal models is complicated by
two issues: firstly, there may be a compensatory regulation of
other drug transporter molecules and, secondly, the wide
Fig. 3 Epileptic seizures trigger an activity-dependent sequence of events resulting in alterations in neuronal firing and pharmacosensitivity.
Known changes triggered by seizures include coordinate changes in ion channel transcription, altered post-translational processing of ion
channel proteins, or altered modification of channels by second-messenger systems. Many of these changes result in defined
pharmacological and functional changes in ion channels. These changes may underlie altered responses to AEDs as well as altered
excitability. It should be noted that this model depicts acquired activity-dependent changes caused by seizures. Reduced responses to AEDs
may also be a pre-existing condition caused by genetic polymorphisms that affect specific AED targets (see discussion in text).
Page 10 of 18 Brain (2005) S. Remy and H. Beck
expression of drug transporters in other tissues may result in
complex pharmacokinetic effects of deleting drug transporter
genes. These issues do not apply when drug transporters are
inhibited pharmacologically in vivo. Indeed, pharmacological
inhibition of drug transporters alters brain distribution of
some AEDs (Potschka and Lo ¨scher, 2001; Potschka et al.,
2001, 2003b; Lo ¨scher and Potschka, 2002, see Table 3). It
employed thus far are not very specific, and that studies using
more specific novel inhibitors are currently being undertaken.
Interestingly, the results in the literature with regard to one
of the most frequently employed AEDs, carbamazepine, are
not uniform. This drug is not transported in PGP-containing
cell systems, and its brain concentration remains unaltered in
mice lacking PGP (Owen et al., 2001), or animals lacking
MRP2 (Potschka et al., 2003a). On the other hand, pharma-
cological (Potschka et al., 2001) or genetic (Rizzi et al., 2002)
intraparenchymal carbamazepine concentration under some
conditions. The reasons for this discrepancy are currently
under scrutiny. That not all AEDs may be transported equally
(Schinkel et al., 1996). As a further possibility, carbamazepine
has been shown to itself inhibit the activity of human
P-glycoprotein, albeit at high concentrations which may
not be clinically relevant (Weiss et al., 2003).
A large body of evidence suggests that different drug trans-
porter molecules are indeed upregulated in human epilepsy,
as well as in experimental models of epilepsy. For instance,
increased MDR1 expression on the mRNA and/or protein
level occurs in patients with different forms of epilepsy
(Tishler et al., 1995; Lazarowski et al., 1999; Sisodiya et al.,
1999, 2002; Aronica et al., 2003; Volk and Lo ¨scher, 2005) and
after chemically-induced status epilepticus or audiogenic
seizures (Zhang et al., 1999; Kwan et al., 2002; Rizzi et al.,
2002). Similar findings have been obtained for MRP1
[(Sisodiya et al., 2001, 2002), MRP2 (Dombrowski et al.,
2001)] and major vault protein (Van Vliet et al., 2004).
These studies have also shown that expression of drug
transporter genes in epileptic foci is observed in cell types
that do not usually express them. For instance, PGP and
MRP1 appear to be strongly upregulated on the protein
level in astrocytes, especially surrounding blood vessels
(Sisodiya et al., 2002). Likewise, there may be upregulation
of drug transporter expression in dysplastic neurons in focal
cortical dysplasia (Sisodiya et al., 2001), as well as in hippo-
Volk et al., 2004). It is yet unclear how this ectopic expression
might contribute to altered pharmacosensitivity. It is entirely
possible, however, that expression of multidrug transporters
in neuronal membranes inhibits access of AEDs to intracel-
lular sites of action.
Relationship of molecular changes in AED
sensitivity to pharmacoresistance
observed in vivo
If multidrug transporters play a significant role in phar-
macoresistance, then upregulation of transporters on the
molecular or functional level should correlate with the clin-
ically observed responsiveness to AEDs. Indeed, increased
drug transporter expression appeared to be correlated with
less efficient seizure control in one study (Tishler et al., 1995).
This correlation is also found inan animalmodelof resistance
to AEDs. Rats resistant to phenobarbital showed a dramatic
overexpression of PGP in limbic brain regions compared to
rats responsive to phenobarbital (Volk and Lo ¨scher, 2005).
Similar findings have been obtained in an elegant study using
MRP2-deficient rats. In this study, MRP2-deficient kindled
rats have higher PHT brain levels than wild-type rats, and are
more susceptible to PHT treatment (Potschka et al., 2003b).
These findings are interesting because they constitute the first
controlled experiment in which deficiency in a specific drug
transporter is associated with differential susceptibility to
Even though, collectively, these findings appear to support
a role for multidrug transporters in pharmacoresistant epi-
lepsy, there are a number of conceptual questions that remain
enigmatic. Firstly, epileptic seizures are known to result in a
disruption of the BBB, which would be expected to result in
better access of AEDs to brain parenchyma despite the
upregulation of multidrug transporters. Secondly, patients
are in many cases treated with AEDs until CNS side effects
develop. This seems to indicate that relevant CNS concentra-
tions of AEDs are reached despite transporter upregulation,
yet, these patients are resistant to treatment. This apparent
discrepancy could potentially arise via local upregulation of
drug transporters that only affects AED concentrations at the
The genetic basis of pharmacoresistance
How can the wide spectrum of pharmacoresistance observed
in human epilepsy patients and some animal models be
explained? A number of recent studies have suggested that
Table 3 Drug efflux transporters and their
anticonvulsant drug substrates (adapted from
Loescher and Potschka, 2005)
Drug efflux transporterSubstrate
PGP (MDR1, ABCB1)Phenytoin (Tishler et al., 1995;
Schinkel et al., 1996; Potschka and
Lo ¨scher, 2001; Rizzi et al., 2002)
Carbamazepine (Potschka et al., 2001)
Phenobarbital (Potschka et al., 2002)
Lamotrigine (Potschka et al., 2002)
Felbamate (Potschka et al., 2002)
Topiramate (Sills et al., 2002)
Phenytoin (Potschka et al., 2003b) MRP2 (ABCC2)
Pharmacoresistance in epilepsy Brain (2005)Page 11 of 18
sequence variants in drug transporter or ion channel genes
affect either function or expression of the corresponding
proteins. In the case of drug transporters, a number of func-
tionally relevant polymorphisms have been identified (Kerb
et al., 2001a, b). Furthermore, a polymorphism (C3435T) has
been identified in exon 25 of the gene encoding MDR1 that
is associated with increased expression of the protein (CC-
genotype). Based on these findings, Siddiqui et al. (2003)
conducted a population-based association study testing the
hypothesis that the C3435T polymorphism is associated with
resistance to AED treatment. They found that patients
with drug-resistant epilepsy were more likely to have the
CC-genotype than the TT-genotype [OR 2.66, 95% CI
suggested by the authors of this study, the C3435T poly-
morphism by itself is very unlikely to confer a biologically
relevant effect. Since this variant is localized in an extensive
block of linkage disequilibrium spanning the gene, the as yet
unidentified causal variant is supposed be in linkage disequi-
librium with the C-allele of the C3435T polymorphism. It
should be noted that the results of Siddiqui et al. (2003)
have not been confirmed in a subsequent study by Tan
et al. (2004). To further address how polymorphisms can
contribute to drug resistance, two major obstacles will have
to be overcome. Firstly, it will be necessary to address experi-
mentally whether polymorphisms found in association stud-
ies have biologically relevant effects. Secondly, it will be
patient cohorts to increase reproducibility of such results
(Soranzo et al., 2004; Cavalleri et al., 2005). Finally, it will
be interesting to extend current studies to include poly-
morphisms in other multidrug transporters. In this respect,
the development of single nucleotide polymorphism tagging
for classes of genes important in resistance is a very important
step that may enable screening of large numbers of patients
(Ahmadi et al., 2005).
It is important to note that gene polymorphisms
relevant for pharmacoresistance may occur both in promoter
regions as well as in introns and exons. Gene polymorphisms
within the coding regions of such genes would result in a
difference in ion channel or transporter proteins that
precedes the onset of epilepsy. Polymorphisms in promoter
regions, which affect the transcription of such genes, may
affect activity-dependent transcriptional regulation of these
genes by seizures. This provides a potential mechanism for
the acquisition of a pharmacoresistant phenotype during
et al., 2003)]. As
Interplay between target and
Collectively, the experimental results described in the
above sections indicate that functionally relevant alterations
in both AED targets and AED transporters exist. Clearly, these
mechanisms are not mutually exclusive. It is entirely possible
that decreased permeation of AEDs into brain tissue, in
synergy with changes in targets for these drugs, mediate phar-
macoresistance. This does not exclude that—for some
AEDs—predominant mechanisms underlying pharmacores-
istance to these drugs can be identified.
Carbamazepine, for instance, appears not to be a substrate
of some multidrug transporters (Owen et al., 2001); rather,
sodium channels display a potent loss of sensitivity to
carbamazepine (Remy et al., 2003a). These and other results
imply that expression of multidrug transporters at the BBB
is not the main factor in the development of resistance,
and imply a target mechanism for this drug. For other
AEDs, this may be different. For instance, intraparenchymal
PHT concentration is potently regulated by multidrug trans-
porters (Potschka and Lo ¨scher, 2001; Rizzi et al., 2002;
Potschka et al., 2003b), and epileptic animals lacking a mul-
tidrug transporter protein (MRP2) are more sensitive to PHT
treatment than wild-type animals (Potschka et al., 2003b). In
contrast, target mechanisms seem to be less important for
PHT compared to carbamazepine (Jeub et al., 2002;
Remy et al., 2003b). Although the evidence supporting this
view is far from conclusive, it is tempting to speculate that
predominant resistance mechanisms may exist for specific
Future directions of research
Whatare thekeypiecesofevidencethat weshould consider to
beprerequisites inorder tostate thatdrug transportersand/or
altered targets play a role in the development of resistance to a
given AED? We believe that the following sets of experimental
results should be available:
(i) Evidence that the multidrug transporter regulates intra-
parenchymal concentrations of the drug: this should
include work with specific drug transporter inhibitors,
and mice lacking specific drug transporter subtypes, as
well as a combination of pharmacological and genetic
inhibition of transporter function.
(ii) Evidence that multidrug transporter expression and/or
transporter function is upregulated in human and
experimental epilepsy. Regarding drug targets, evidence
should be available that drug targets are less sensitive to a
given AED in chronic epilepsy. In both cases, functional
and molecular changes should correlate with AED sens-
itivity of seizures in experimental animals or epilepsy
(iii) Evidence that genetic or pharmacological manipulation
of drug transporters/drug targets affects sensitivity of
spontaneous seizures to AEDs in vivo in chronic models
In addition, the following data on human epilepsy patients
should be obtained.
(iv) Association of polymorphisms in drug transporter/drug
target genes with clinical pharmacoresistance. This could
also include association of polymorphisms with the drug
Page 12 of 18Brain (2005) S. Remy and H. Beck
transporter function or drug target pharmacology
measured in vitro in tissue obtained from epilepsy
(v) Demonstration thatdrug
isms have functional effects resulting in a decreased
intraparenchymal AED concentration (i.e. effects on
either expression or function of drug transporter
molecules). Likewise, polymorphisms in drug target
genes should have demonstrable effects on expression
or pharmacology of these targets.
Fig. 4 Potential implications for treatment of pharmacoresistant epilepsy when taking into account different mechanisms underlying
pharmacoresistance. Responsive patients (A): In patients responsive to a given AED, the AED gains sufficient access to a target. In addition,
the AED has sufficient pharmacological effects on the target. Resistant patients, predominant transporter mechanism of resistance (B): In a
scenario of increased drug transport without any changes in the AED target, the use of AEDs that are not transporter substrates and may
additionally exhibit transporter-inhibiting properties would be advantageous in obtaining therapeutic drug levels at the site of action.
Alternatively, the use of transporter inhibitors may increase the intraparenchymal drug concentration to therapeutic levels and may help to
overcome the reduced efficacy of the drug. Resistant patients, predominant target mechanism of resistance (C): If resistance for a given
AED is due to a change in its target, increasing the intraparenchymal AED concentration by comedication with transporter inhibitors would
not be expected to be beneficial. In this case, the development of drugs that specifically act on the modified target would be the more
appropriate approach. Resistant patients, mixed resistance mechanism (D): If both transporter- and target-mediated mechanisms of
resistance apply, both strategies outlined in panel B and C would have to be combined.
Pharmacoresistance in epilepsyBrain (2005)Page 13 of 18
Potential future clinical implications
Once we have obtained a detailed picture of the mechanisms
underlying the development of pharmacoresistance to
individual AEDs, this knowledge may become increasingly
important both in drug development, as well as clinically.
First, detailed information on drug target changes can be
used to inform the development of new drugs for the treat-
ment of epilepsy. Currently, identification of AEDs is per-
formed mostlyin acute
experimental animals. These animals do not show any of
the chronic changes in ion channels or receptors discussed
here, and may not represent the best models to develop novel
compounds useful in human epilepsy. Targeting novel drugs
to ‘epileptic’ ion channels based on information from chronic
models of epilepsy or even tissue from epileptic patients
represents a promising avenue for rational drug development
in the future.
Information on specific resistance mechanisms might also
be used to guide potential treatment with drug transporter
inhibitors in conjunction with AEDs.The simplestscenario in
which such substances might be used would be as comedica-
tion with an AED that is ineffective predominantly due to
transporter-mediated mechanisms (depicted schematically in
Fig. 4B). On the other hand, comedication with transporter
inhibitors in a patient in whom resistance to an AED is
predominantly target mediated (see Fig. 4C) would not be
expected to be beneficial. In this case, the development of
drugs that specifically act on the modified target would be
the more appropriate approach. Ideally, these compounds
would not be substrates of drug transporter, but could also
be coadministered with transporter inhibitors. For some
AEDs, both resistance mechanisms may be relevant and syn-
ergistic (Fig. 4D); in this case, strategies to overcome resist-
ance would have to combine the approaches outlined in
Fig. 4B and C. A further clinical issue that may gain more
and more importance in the coming years is the identification
of predictors that identify clinically resistant or responsive
patient populations. If clear genetic polymorphisms in either
transporteror ion channelgenes can be identifiedthat reliably
predict the occurrence and the probable mechanism of drug
resistance(Soranzo et al., 2004; Tan et al., 2004; Ahmadi et al.,
2005), these data would obviously strongly influence initial
therapy, and perhaps increase the chances of its success.
Ahmadi KR, Weale ME, Xue ZY, Soranzo N, Yarnall DP, Briley JD, et al. A
single-nucleotide polymorphism tagging set for human drug metabolism
and transport. Nat Genet 2005; 37: 84–9.
Aicardi J, Shorvon SD. Intractable epilepsy. In: Engel J, Pedley TA, editors.
Epilepsy:acomprehensive textbook.Philadelphia:Lippincott-Raven; 1997.
Alden KJ, Garcia J. Differential effect of gabapentin on neuronal and muscle
calcium currents. J Pharmacol Exp Ther 2001; 297: 727–35.
Aronica E, Yankaya B, Troost D, van Vliet EA, Lopes da Silva FH, Gorter JA.
Induction of neonatal sodium channel II and III alpha-isoform mRNAs in
Neurosci 2001; 13: 1261–6.
Aronica E, Gorter JA, Jansen GH, van Veelen CW, van Rijen PC,
Leenstra S, et al. Expression and cellular distribution of multidrug trans-
porter proteins in two major causes of medically intractable epilepsy: focal
cortical dysplasia and glioneuronal tumors. Neuroscience 2003; 118:
Bartolomei F, Gastaldi M, Massacrier A, Planells R, Nicolas S, Cau P. Changes
in the mRNAs encoding subtypes I, II and III sodium channel alpha
subunits following kainate-induced seizures in rat brain. J Neurocytol
1997; 26: 667–78.
Batrakova EV, Li S, Miller DW, Kabanov AV. Pluronic P85 increases
permeability of a broad spectrum of drugs in polarized BBMEC and
Caco-2 cell monolayers. Pharm Res 1999; 16: 1366–72.
Ben Menachem E. Pregabalin pharmacology and its relevance to clinical
practice. Epilepsia 2004; 45 Suppl 6: 13–8.
Bender RA, Soleymani SV, Brewster AL, Nguyen ST, Beck H, Mathern GW,
et al. Enhanced expression of a specific hyperpolarization-activated cyclic
nucleotide-gated cation channel (HCN) in surviving dentate gyrus granule
cells of human and experimental epileptic hippocampus. J Neurosci 2003;
Bernard C, Anderson A, Becker A, Poolos NP, Beck H, Johnston D. Acquired
dendritic channelopathy in temporal lobe epilepsy. Science 2004; 305:
Borst P, Evers R, Kool M, Wijnholds J. A family of drug transporters: the
multidrug resistance-associated proteins. J Natl Cancer Inst 2000; 92:
Brooks-Kayal AR, Shumate MD, Jin H, Rikhter TY, Coulter DA. Selective
temporal lobe epilepsy. Nat Med 1998; 4: 1166–72.
Brooks-Kayal AR, Shumate MD, Jin H, Lin DD, Rikhter TY, Holloway KL,
et al. Human neuronal gamma-aminobutyric acid(A) receptors: coordin-
ated subunit mRNA expression and functional correlates in individual
dentate granule cells. J Neurosci 1999; 19: 8312–8.
Catterall WA. Molecular properties of brain sodium channels: an important
target for anticonvulsant drugs. Adv Neurol 1999; 79: 441–56.
Cavalleri GL, Lynch JM, Depondt C, Burley MW, Wood NW, Sisodiya SM,
et al. Failure to replicate previously reported genetic associations with
sporadic temporal lobe epilepsy: where to from here? Brain 2005; 128:
Chao TI, Alzheimer C. Effects of phenytoin on the persistent Na+current of
mammalian CNS neurones. NeuroReport 1995; 6: 1778–80.
Chappell AS, Sander JW, Brodie MJ, Chadwick D, Lledo A, Zhang D, et al. A
crossover, add-on trial of talampanel in patients with refractory partial
seizures. Neurology 2002; 58: 1680–2.
modified h-channels after complex febrile seizures convert the seizure-
induced enhancement of inhibition to hyperexcitability. Nat Med 2001;
Cohen I, Navarro V, Clemenceau S, Baulac M, Miles R. On the origin of
interictal activity in human temporal lobe epilepsy in vitro. Science 2002;
Cohen AS, Lin DD, Quirk GL, Coulter DA. Dentate granule cell GABA(A)
receptors in epileptic hippocampus: enhanced synaptic efficacy and altered
pharmacology. Eur J Neurosci 2003; 17: 1607–16.
Costa E. From GABAA receptor diversity emerges a unified vision
of GABAergic inhibition. Annu Rev Pharmacol Toxicol 1998; 38:
Coulter DA, Huguenard JR, Prince DA. Characterization of ethosuximide
reduction of low-threshold calcium current in thalamic neurons. Ann
Neurol 1989; 25: 582–93.
Curia G, Aracri P, Sancini G, Mantegazza M, Avanzini G, Franceschetti S.
Protein-kinase C-dependent phosphorylation inhibits the effect of the
Neuroscience 2004; 127: 63–8.
GABA uptake inhibitors. Neuropharmacology 2000; 39: 2399–407.
Dean M, Rzhetsky A, Allikmets R. The human ATP-binding cassette (ABC)
transporter superfamily. Genome Res 2001; 11: 1156–66.
Page 14 of 18 Brain (2005) S. Remy and H. Beck
Decleves X, Regina A, Laplanche JL, Roux F, Boval B, Launay JM, et al.
Functional expression of P-glycoprotein and multidrug resistance-
associated protein (Mrp1) in primary cultures of rat astrocytes. J Neurosci
Res 2000; 60: 594–601.
Dombrowski SM, Desai SY, Marroni M, Cucullo L, Goodrich K, Bingaman
W, et al. Overexpression of multiple drug resistance genes in endothelial
cells from patients with refractory epilepsy. Epilepsia 2001; 42: 1501–6.
Eghbali M, Curmi JP, Birnir B, Gage PW. Hippocampal GABA(A) channel
conductance increased by diazepam. Nature 1997; 388: 71–5.
Ellerkmann RK, Remy S, Chen J, Sochivko D, Elger CE, Urban BW, et al.
Molecular and functional changes in voltage-dependent Na+channels fol-
lowing pilocarpine-induced status epilepticus in rat dentate granule cells.
Neuroscience 2003; 119: 323–33.
Ertel EA, Campbell KP, Harpold MM, Hofmann F, Mori Y, Perez-Reyes E,
et al. Nomenclature of voltage-gated calcium channels. Neuron 2000; 25:
Ffrench-Mullen JM, Barker JL, Rogawski MA. Calcium current block by
(?)-pentobarbital, phenobarbital, and CHEB but not (+)-pentobarbital
in acutely isolated hippocampal CA1 neurons: comparison with effects
on GABA-activated Cl?current. J Neurosci 1993; 13: 3211–21.
Fink K, Meder W, Dooley DJ, Go ¨thert M. Inhibition of neuronal Ca2+influx
by gabapentin and subsequent reduction of neurotransmitter release from
rat neocortical slices. Br J Pharmacol 2000; 130: 900–6.
Fink-Jensen A, Suzdak PD, Swedberg MD, Judge ME, Hansen L, Nielsen PG.
The gamma-aminobutyric acid (GABA) uptake inhibitor, tiagabine,
increases extracellular brain levels of GABA in awake rats. Eur J Pharmacol
1992; 220: 197–201.
Fohlmeister JF, Adelman WJ Jr, Brennan JJ. Excitable channel currents and
gating times in the presence of anticonvulsants ethosuximide and
valproate. J Pharmacol Exp Ther 1984; 230: 75–81.
Frahm C, Stief F, Zuschratter W, Draguhn A. Unaltered control of extracel-
pilocarpine-induced status epilepticus. Epilepsy Res 2003; 52: 243–52.
Freiman TM, Kukolja J, Heinemeyer J, Eckhardt K, Aranda H, Rominger A,
et al. Modulation of K+-evoked [3H]-noradrenaline release from rat and
human brain slices by gabapentin: involvement of KATPchannels. Naunyn
Schmiedebergs Arch Pharmacol 2001; 363: 537–42.
Gastaldi M, Bartolomei F, Massacrier A, Planells R, Robaglia-Schlupp A, Cau
P. Increase in mRNAs encoding neonatal II and III sodium channel
alpha-isoforms during kainate-induced seizures in adult rat hippocampus.
Brain Res Mol Brain Res 1997; 44: 179–90.
Gastaldi M, Robaglia-Schlupp A, Massacrier A, Planells R, Cau P. mRNA
coding for voltage-gated sodium channel beta2 subunit in rat central
nervous system: cellular distribution and changes following kainate-
induced seizures. Neurosci Lett 1998; 249: 53–6.
Gebhardt C, Breustedt JM, Noldner M, Chatterjee SS, Heinemann U. The
antiepileptic drug losigamone decreases the persistent Na+current in rat
hippocampal neurons. Brain Res 2001; 920: 27–31.
Gee NS, Brown JP, Dissanayake VU, Offord J, Thurlow R, Woodruff GN. The
novel anticonvulsant drug, gabapentin (Neurontin), binds to the a2d
subunit of a calcium channel. J Biol Chem 1996; 271: 5768–76.
Gibbs JW III, Shumate M, Coulter D. Differential epilepsy-associated
alerations in postsynaptic GABAAreceptor function in dentate granule
and CA1 neurons. J Neurophysiol 1997; 77: 1924–38.
Gibbs JW III, Sombati S, DeLorenzo RJ, Coulter DA. Cellular actions of
topiramate: blockade of kainate-evoked inward currents in cultured
hippocampal neurons. Epilepsia 2000; 41 Suppl 1: S10–S16.
Golden PL, Pardridge WM. P-Glycoprotein on astrocyte foot processes of
unfixed isolated human brain capillaries. Brain Res 1999; 819: 143–6.
Golden PL, Pardridge WM. Brain microvascular P-glycoprotein and a revised
model of multidrug resistance in brain. Cell Mol Neurobiol 2000; 20:
Goldin AL. Diversity of mammalian voltage-gated sodium channels. Ann N Y
Acad Sci 1999; 868: 38–50.
Goldin AL, Barchi RL, Caldwell JH, Hofmann F, Howe JR, Hunter JC,
et al. Nomenclature of voltage-gated sodium channels. Neuron 2002;
T-type calcium channels by succinimide antiepileptic drugs. Mol
Pharmacol 2001; 60: 1121–32.
Gordey M, DeLorey TM, Olsen RW. Differential sensitivity of recombinant
GABA(A) receptors expressed in Xenopus oocytes to modulation by
topiramate. Epilepsia 2000; 41 Suppl 1: S25–S29.
Gryder DS, Rogawski MA. Selective antagonism of GluR5 kainate-receptor-
mediated synaptic currents by topiramate in rat basolateral amygdala
neurons. J Neurosci 2003; 23: 7069–74.
Gulledge AT, Stuart GJ. Excitatory actions of GABA in the cortex. Neuron
2003; 37: 299–309.
Harty TP, Rogawski MA. Felbamate block of recombinant N-methyl-D-
aspartate receptors: selectivity for the NR2B subunit. Epilepsy Res 2000;
Herrero AI, Del Olmo N, Gonzalez-Escalada JR, Solis JM. Two new actions of
topiramate: inhibition of depolarizing GABA(A)-mediated responses and
activation of a potassium conductance. Neuropharmacology 2002; 42:
Huai-Yun H, Secrest DT, Mark KS, Carney D, Brandquist C, Elmquist WF,
et al. Expression ofmultidrug resistance-associated protein (MRP)in brain
microvessel endothelial cells. Biochem Biophys Res Commun 1998; 243:
Huang CW, Huang CC, Liu YC, Wu SN. Inhibitory effect of lamotrigine on
A-type potassium current in hippocampal neuron-derived H19-7 cells.
Epilepsia 2004; 45: 729–36.
Huguenard JR. Low-threshold calcium currents in central nervous system
neurons. Annu Rev Physiol 1996; 58: 329–48.
Huguenard JR. Block of T-type calcium channels is an important action of
succinimide antiabsence drugs. Epilepsy Curr 2002; 2: 49–52.
Isokawa M, Levesque MF. Increased NMDA responses and dendritic
degeneration in human epileptic hippocampal neurons in slices. Neurosci
Lett 1991; 132: 212–6.
Jeub M, Beck H, Siep E, Ruschenschmidt C, Speckmann EJ, Ebert U, et al.
Effect of phenytoin on sodium and calcium currents in hippocampal CA1
neurons of phenytoin-resistant kindled rats. Neuropharmacology 2002; 42:
Jolkkonen J, Mazurkiewicz M, Lahtinen H, Riekkinen P. Acute effects of
gamma-vinyl GABA on the GABAergic system in rats as studied by
microdialysis. Eur J Pharmacol 1992; 229: 269–72.
Kearney JA, Plummer NW, Smith MR, Kapur J, Cummins TR, Waxman SG,
in seizures and behavioral abnormalities. Neuroscience 2001; 102: 307–17.
Kerb R, Aynacioglu AS, Brockmoller J, Schlagenhaufer R, Bauer S, Szekeres T,
et al. The predictive value of MDR1, CYP2C9, and CYP2C19 polymorph-
isms for phenytoin plasma levels. Pharmacogenomics J 2001a; 1: 204–10.
Kerb R, Hoffmeyer S, Brinkmann U. ABC drug transporters: hereditary poly-
morphisms and pharmacological impact in MDR1, MRP1 and MRP2.
Pharmacogenomics 2001b; 2: 51–64.
Kleckner NW, Glazewski JC, Chen CC, Moscrip TD. Subtype-selective
antagonism of N-methyl-D-aspartate receptors by felbamate: insights
into the mechanism of action. J Pharmacol Exp Ther 1999; 289: 886–94.
Ko ¨hling R. Voltage-gated sodium channels in epilepsy. Epilepsia 2002; 43:
Kohr G, De Koninck Y, Mody I. Properties of NMDA receptor channels in
neurons acutely isolated from epileptic (kindled) rats. J Neurosci 1993; 13:
Kuo CC. A common anticonvulsant binding site for phenytoin, car-
bamazepine, and lamotrigine in neuronal Na+channels. Mol Pharmacol
1998; 54: 712–21.
Kuo CC, Lin BJ, Chang HR, Hsieh CP. Use-dependent inhibition of the
N-methyl-D-aspartate currents by felbamate: a gating modifier with
selective binding to the desensitized channels. Mol Pharmacol 2004; 65:
Kwan P, Brodie MJ. Early identification of refractory epilepsy. N Engl J Med
2000; 342: 314–9.
Kwan P, Brodie MJ. Potential role of drug transporters in the pathogenesis of
medically intractable epilepsy. Epilepsia 2005; 46: 224–35.
Pharmacoresistance in epilepsyBrain (2005)Page 15 of 18
Kwan P, Sills GJ, Butler E, Gant TW, Meldrum BS, Brodie MJ.
Regional expression of multidrug resistance genes in genetically
epilepsy-prone rat brain after a single audiogenic seizure. Epilepsia
2002; 43: 1318–23.
Lacinova L. Pharmacology of recombinant low-voltage activated calcium
channels. Curr Drug Targets CNS Neurol Disord 2004; 3: 105–11.
Lampl I, Schwindt P, Crill W. Reduction of cortical pyramidal neuron
excitability by the action of phenytoin on persistent Na+current. J Phar-
macol Exp Ther 1998; 284: 228–37.
Lazarowski A, Sevlever G, Taratuto A, Massaro M, Rabinowicz A. Tuberous
sclerosis associated with MDR1 gene expression and drug-resistant
epilepsy. Pediatr Neurol 1999; 21: 731–4.
Leite JP, CavalheiroEA. Effectsof conventionalantiepilepticdrugsin a model
of spontaneous recurrent seizures in rats. Epilepsy Res 1995; 20: 93–104.
Leresche N, Parri HR, Erdemli G, Guyon A, Turner JP, Williams SR, et al. On
the action of the anti-absence drug ethosuximide in the rat and cat
thalamus. J Neurosci 1998; 18: 4842–53.
Lo ¨scher W. Valproate enhances GABA turnover in the substantia nigra. Brain
Res 1989; 501: 198–203.
Lo ¨scher W, Horstermann D. Differential effects of vigabatrin, gamma-
acetylenic GABA, aminooxyacetic acid, and valproate on levels of various
amino acids in rat brain regions and plasma. Naunyn Schmiedebergs Arch
Pharmacol 1994; 349: 270–8.
Lo ¨scher W, Potschka H. Role of multidrug transporters in pharmacoresist-
ance to antiepileptic drugs. J Pharmacol Exp Ther 2002; 301: 7–14.
Lo ¨scher W, Potschka H. Drug resistance in brain diseases and the role of drug
efflux transporters. Nat Rev Neurosci 2005; 6: 591–602.
Lo ¨scher W, Cramer S, Ebert U. Selection of phenytoin responders and
nonresponders in male and female amygdala-kindled Sprague-Dawley
rats. Epilepsia 1998; 39: 1138–47.
Lossin C, Wang DW, Rhodes TH, Vanoye CG, George AL Jr. Molecular basis
of an inherited epilepsy. Neuron 2002; 34: 877–84.
Lucas PT, Meadows LS, Nicholls J, Ragsdale DS. An epilepsy mutation in the
beta1 subunit of the voltage-gated sodium channel results in reduced
channel sensitivity to phenytoin. Epilepsy Res 2005; 64: 77–84.
Lukyanetz EA, Shkryl VM, Kostyuk PG. Selective blockade of N-type calcium
channels by levetiracetam. Epilepsia 2002; 43: 9–18.
Madeja M, Margineanu DG, Gorji A, Siep E, Boerrigter P, Klitgaard H, et al.
antiepileptic mechanism of action? Neuropharmacology 2003; 45: 661–71.
Main MJ, Cryan JE, Dupere JR, Cox B, Clare JJ, Burbidge SA. Modulation of
KCNQ2/3 potassium channels by the novel anticonvulsant retigabine. Mol
Pharmacol 2000; 58: 253–62.
Marchi N, Hallene KL, Kight KM, Cucullo L, Moddel G, Bingaman W, et al.
Significance of MDR1 and multiple drug resistance in refractory human
epileptic brain. BMC Med 2004; 2: 37.
Martin D, McNamara JO, Nadler JV. Kindling enhances sensitivity of CA3
hippocampal pyramidal cells to NMDA. J Neurosci 1992; 12: 1928–35.
McClelland D, Evans RM, Barkworth L, Martin DJ, Scott RH. A study com-
paringtheactions of gabapentinand pregabalinon theelectrophysiological
properties of cultured DRG neurones from neonatal rats. BMC Pharmacol
2004; 4: 14.
McLean MJ, Macdonald RL. Sodium valproate, but not ethosuximide,
produces use- and voltage- dependent limitation of high frequency repet-
itive firing of action potentials of mouse central neurons in cell culture.
J Pharmacol Exp Ther 1986; 237: 1001–11.
McLean MJ, Schmutz M, Wamil AW, Olpe HR, Portet C, Feldmann KF.
Oxcarbazepine: mechanisms of action. Epilepsia 1994; 35 Suppl 3: S5–S9.
McLean MJ, Bukhari AA, Wamil AW. Effects of topiramate on sodium-
dependent action-potential firing by mouse spinal cord neurons in cell
culture. Epilepsia 2000; 41 Suppl 1: S21–S24.
Mody I, Heinemann U. NMDA receptors of dentate gyrus granule cells
participate in synaptic transmission following kindling. Nature 1987;
Mody I, Pearce RA. Diversity of inhibitory neurotransmission through
GABA(A) receptors. Trends Neurosci 2004; 27: 569–75.
Niespodziany I, Klitgaard H, Margineanu DG. Is the persistent sodium cur-
rent a specific target of anti-absence drugs? NeuroReport 2004; 15:
Nissinen JPT, Pitka ¨nen A. An animal model with spontaneous seizures: a
new tool for testing the effects of antiepileptic compounds. Epilepsia 2000;
Nobile M, Lagostena L. A discriminant block among K+channel types
by phenytoin in neuroblastoma cells. Br J Pharmacol 1998; 124: 1698–702.
Owen A, Pirmohamed M, Tettey JN, Morgan P, Chadwick D, Park BK.
Carbamazepine is not a substrate for P-glycoprotein. Br J Clin Pharmacol
2001; 51: 345–9.
Pardridge WM, Golden PL, Kang YS, Bickel U. Brain microvascular and
astrocyte localization of P-glycoprotein. J Neurochem 1997; 68: 1278–85.
Poolos NP, Migliore M, Johnston D. Pharmacological upregulation of
h-channels reduces the excitability of pyramidal neuron dendrites. Nat
Neurosci 2002; 5: 767–74.
Potschka H, Lo ¨scher W. In-vivo evidence for P-glycoprotein-mediated trans-
port of phenytoin at the blood-brain barrier of rats. Epilepsia 2001; 42:
Potschka H, Fedrowitz M, Lo ¨scher W. P-glycoprotein and multidrug
resistance-associated protein are involved in the regulation of extracellular
levels of the major antiepileptic drug carbamazepine in the brain.
Neuroreport 2001; 12: 3557–60.
Potschka H, Fedrowitz M, Lo ¨scher W. P-Glycoprotein-mediated efflux of
phenobarbital, lamotrigine, and felbamate at the blood-brain barrier:
evidence from microdialysis experiments in rats. Neurosci Lett 2002;
Potschka H, Fedrowitz M, Lo ¨scher W. Brain access and anticonvulsant
efficacy of carbamazepine, lamotrigine, and felbamate in ABCC2/MRP2-
deficient TR- rats. Epilepsia 2003a; 44: 1479–86.
Potschka H, Fedrowitz M, Lo ¨scher W. Multidrug resistance protein MRP2
contributes to blood-brain barrier function and restricts antiepileptic drug
activity. J Pharmacol Exp Ther 2003b; 306: 124–31.
Qian J, Noebels JL. Topiramate alters excitatory synaptic transmission in
mouse hippocampus. Epilepsy Res 2003; 55: 225–33.
Ragsdale DS, Avoli M. Sodium channels as molecular targets for antiepileptic
drugs. Brain Res Brain Res Rev 1998; 26: 16–28.
Ragsdale DS, Scheuer T, Catterall WA. Frequency and voltage-dependent
inhibition of type IIA Na+channels, expressed in a mammalian cell
line, by local anesthetic, antiarrhythmic, and anticonvulsant drugs. Mol
Pharmacol 1991; 40: 756–65.
Rao VV, Dahlheimer JL, Bardgett ME, Snyder AZ, Finch RA, Sartorelli AC,
et al. Choroid plexus epithelial expression of MDR1 P-glycoprotein and
cerebrospinal-fluid drug-permeability barrier. Proc Natl Acad Sci USA
1999; 96: 3900–5.
Reckziegel G, Beck H, Schramm J, Urban BW, Elger CE. Carbamazepine
effects on Na+currents in human dentate granule cells from epileptogenic
tissue. Epilepsia 1999; 40: 401–7.
RegestaG, TanganelliP. Clinicalaspectsandbiologicalbasesof drug-resistant
epilepsies. Epilepsy Res 1999; 34: 109–22.
Regina A, Koman A, Piciotti M, El Hafny B, Center MS, Bergmann R, et al.
Mrp1 multidrug resistance-associated protein and P-glycoprotein expres-
sion in rat brain microvessel endothelial cells. J Neurochem 1998; 71:
Remy S, Gabriel S, Urban BW, Dietrich D, Lehmann TN, Elger CE, et al. A
novel mechanism underlying drug-resistance in chronic epilepsy. Ann
Neurol 2003a; 53: 469–79.
Remy S, Urban BW, Elger CE, Beck H. Anticonvulsant pharmacology of
voltage-gated Na+channels in hippocampal neurons of control and chron-
ically epileptic rats. Eur J Neurosci 2003b; 17: 2648–58.
Rho JM, Donevan SD, Rogawski MA. Barbiturate-like actions of the propa-
nediol dicarbamates felbamate and meprobamate. J Pharmacol Exp Ther
1997; 280: 1383–91.
Rhodes TH, Lossin C, Vanoye CG, Wang DW, George AL Jr. Noninactivating
voltage-gated sodium channels in severe myoclonic epilepsy of infancy.
Proc Natl Acad Sci USA 2004; 101: 11147–52.
contribute tothe blood-
Page 16 of 18Brain (2005) S. Remy and H. Beck
Rizzi M, Caccia S, Guiso G, Richichi C, Corter JA, Aronica E, et al. Limbic
seizures induce P-glycoprotein in rodent brain: functional implications for
pharmacoresistance. J Neurosci 2002; 22: 5833–9.
Robinson RB, Siegelbaum SA. Hyperpolarization-activated cation currents:
from molecules to physiological function. Annu Rev Physiol 2003; 65:
Rogers CJ, Twyman RE, Macdonald RL. Benzodiazepine and b-carboline
regulation of single GABAAreceptor channels of mouse spinal neurones
in culture. J Physiol (Lond) 1994; 475: 69–82.
Rudolph U, Crestani F, Benke D, Brunig I, Benson JA, Fritschy JM, et al.
receptor subtypes. Nature 1999; 401: 796–800.
Rudolph U, Crestani F, Mohler H. GABA(A) receptor subtypes: dissecting
their pharmacological functions. Trends Pharmacol Sci 2001; 22: 188–94.
Sanabria ERG, Su H, Yaari Y. Initiation of network bursts by Ca2+-dependent
intrinsic bursting in the rat pilocarpine model of temporal lobe epilepsy. J
Physiol 2001; 205–16.
Res 1987; 413: 185–8.
Schinkel AH, Wagenaar E, Mol CA, Van Deemter L. P-glycoprotein in the
blood-brain barrier of mice influences the brain penetration and pharma-
cological activity of many drugs. J Clin Invest 1996; 97: 2517–24.
Schinkel AH, Mayer U, Wagenaar E, Mol CA, van Deemter L, Smitt JJ, et al.
Normal viability and altered pharmacokinetics in mice lacking mdr1-type
(drug-transporting) P-glycoproteins. Proc Natl Acad Sci USA 1997; 94:
Schmutz M, Brugger F, Gentsch C, McLean MJ, Olpe HR. Oxcarbazepine:
preclinical anticonvulsant profile and putative mechanisms of action.
Epilepsia 1994; 35 Suppl 5: S47–S50.
Schumacher TB, Beck H, Steinhauser C, Schramm J, Elger CE. Effects of
phenytoin, carbamazepine, and gabapentin on calcium channels in hippo-
campal granule cells from patients with temporal lobe epilepsy. Epilepsia
1998; 39: 355–63.
Schwarz JR, Grigat G. Phenytoin and carbamazepine: potential- and
frequency-dependent block of Na currents in mammalian myelinated
nerve fibers. Epilepsia 1989; 30: 286–94.
Segal MM, Douglas AF. Late sodium channel openings underlying epilepti-
form activity are preferentially diminished by the anticonvulsant pheny-
toin. J Neurophysiol 1997; 77: 3021–34.
Shah MM, Anderson AE, Leung V, Lin X, Johnston D. Seizure-induced
plasticity of h channels in entorhinal cortical layer III pyramidal neurons.
Neuron 2004; 44: 495–508.
Siddiqui A, Kerb R, Weale ME, Brinkmann U, Smith A, Goldstein DB, et al.
Associationof multidrug resistance in epilepsy with a polymorphism in the
drug-transporter gene ABCB1. N Engl J Med 2003; 348: 1442–8.
Sills GJ, Kwan P, Butler E, de Lange EC, van den Berg DJ, Brodie MJ.
P-glycoprotein-mediated efflux of antiepileptic drugs: preliminary studies
in mdr1a knockout mice. Epilepsy Behav 2002; 3: 427–32.
Silverman JA, Raunio H, Gant TW, Thorgeirsson SS. Cloning and charac-
terization of a member of the rat multidrug resistance (mdr) gene family.
Gene 1991; 106: 229–36.
Sisodiya SM, Heffernan J, Squier MV. Over-expression of P-glycoprotein in
malformations of cortical development. Neuroreport 1999; 10: 3437–41.
focal cortical dysplasia. Lancet 2001; 357: 42–3.
Sisodiya SM, Lin WR, Harding BN, Squier MV, Thom M. Drug resistance in
epilepsy: expression of drug resistance proteins in common causes of
refractory epilepsy. Brain 2002; 125: 22–31.
Soranzo N, Cavalleri GL, Weale ME, Wood NW, Despondt C, Marguerie R,
et al. Identifyingcandidatecausal variants responsible for altered activity of
the ABCB1 multidrug resistance gene. Genome Res 2004; 14: 1333–44.
Spadoni F, Hainsworth AH, Mercuri NB, Caputi L, Martella G, Lavaroni F,
et al. Lamotrigine derivatives andriluzole inhibitINa,P incortical neurons.
Neuroreport 2002; 13: 1167–70.
Spampanato J, Kearney JA, de Haan G, McEwen DP, Escayg A, Aradi I, et al.
A novel epilepsy mutation in the sodium channel SCN1A identifies a
cytoplasmic domain for beta subunit interaction. J Neurosci 2004; 24:
Sperk G, Furtinger S, Schwarzer C, Pirker S. GABA and its receptors in
epilepsy. Adv Exp Med Biol 2004; 548: 92–103.
Stefani A, Pisani A, De Murtas M, Mercuri NB, Marciani MG, Calabresi P.
Action of GP 47779, the active metabolite of oxcarbazepine, on the
corticostriatal system. II. Modulation of high-voltage-activated calcium
currents. Epilepsia 1995; 36: 997–1002.
Stefani A, Spadoni F, Bernardi G. Differential inhibition by riluzole, lamo-
trigine, and phenytoin of sodium and calcium currents in cortical neurons:
Stefani A, Spadoni F, Bernardi G. Voltage-activated calcium channels: targets
of antiepileptic drug therapy? Epilepsia 1997b; 38: 959–65.
Stefani A, Spadoni F, Bernardi G. Gabapentin inhibits calcium currents in
isolated rat brain neurons. Neuropharmacology 1998; 37: 83–91.
Study RE, Barker JL. Diazepam and (?)-pentobarbital: fluctuation analysis
responses in cultured central neurons. Proc Natl Acad Sci USA 1981; 78:
SuH, AlroyG, KirsonED,YaariY.Extracellularcalciummodulatespersistent
sodium current-dependent intrinsic bursting in rat hippocampal neurons.
J Neurosci 2001; 21: 4173–82.
Su H, Sochivko D, Becker A, Chen J, Jiang Y Yaari Y, et al. Upregulation of a
T-type Ca2+channel causes a long-lasting modification of neuronal firing
mode after status epilepticus. J Neurosci 2002; 22: 3645–55.
Subramaniam S, Rho JM, Penix L, Donevan SD, Fielding RP, Rogawski MA.
Felbamate block of the N-methyl-D-aspartate receptor. J Pharmacol Exp
Ther 1995; 273: 878–86.
SurgesR, Freiman TM,Feuerstein
hyperpolarization-activated cation current Ih in rat CA1 pyramidal cells.
Epilepsia 2003; 44: 150–6.
Suzuki S, Kawakami K, Nishimura S, Watanabe Y, Yagi K, Seino M, et al.
Zonisamide blocks T-type calcium channel in cultured neurons of rat
cerebral cortex. Epilepsy Res 1992; 12: 21–7.
Taglialatela M, Ongini E, Brown AM, Di Renzo G, Annunziato L. Felbamate
inhibits cloned voltage-dependent Na+channels from human and rat
brain. Eur J Pharmacol 1996; 316: 373–7.
Tan NC, Heron SE, Scheffer IE, Pelekanos JT, McMahon JM, Vears DF, et al.
Failure to confirm association of a polymorphism in ABCB1 with
multidrug-resistant epilepsy. Neurology 2004; 63: 1090–2.
Tate SK, Depondt C, Sisodiya SM, Cavalleri GL, Schorge S, Soranzo N, et al.
Genetic predictors of the maximum doses patients receive during clinical
use of the anti-epileptic drugs carbamazepine and phenytoin. Proc Natl
Acad Sci USA 2005; 102: 5507–12.
Tatulian L, Delmas P, Abogadie FC, Brown DA. Activation of expressed
by the anti-convulsant drug retigabine. J Neurosci 2001; 21: 5535–45.
Taverna S, Mantegazza M, Franceschetti S, Avanzini G. Valproate selectively
reduces the persistent fraction of Na+current in neocortical neurons.
Epilepsy Res 1998; 32: 304–8.
Taverna S, Sancini G, Mantegazza M, Franceschetti S, Avanzini G. Inhibition
of transient and persistent Na+current fractions by the new anticonvulsant
topiramate. J Pharmacol Exp Ther 1999; 288: 960–8.
Thompson SM, Ga ¨hwiler BH. Effects of the GABA uptake inhibitor tiagabine
on inhibitory synaptic potentials in rat hippocampal slice cultures.
J Neurophysiol 1992; 67: 1698–701.
Tishler DM, Weinberg KI, Hinton DR, Barbaro N, Annett GM, Raffel C.
MDR1 gene expression in brain of patients with medically intractable
epilepsy. Epilepsia 1995; 36: 1–6.
Todorovic SM, Lingle CJ. Pharmacological properties of T-type Ca2+current
in adult rat sensory neurons: effects of anticonvulsant and anesthetic
agents. J Neurophysiol 1998; 79: 240–52.
Todorovic SM, Perez-Reyes E, Lingle CJ. Anticonvulsants but not general
anesthetics have differential blocking effects on different T-type current
variants. Mol Pharmacol 2000; 58: 98–108.
Pharmacoresistance in epilepsyBrain (2005)Page 17 of 18
Twyman RE, Rogers CJ, Macdonald RL. Differential regulation of gamma-
aminobutyric acid receptor channels by diazepam and phenobarbital.
Ann Neurol 1989a; 25: 213–20.
Twyman RE, Rogers CJ, Macdonald RL. Pentobarbital and picrotoxin have
Ueda K, Shimabuku AM, Konishi H, Fujii Y, Takebe S, Nishi K, et al. Func-
tional expression of human P-glycoprotein in Schizosaccharomyces
pombe. FEBS Lett 1993; 330: 279–82.
Van Vliet EA, Aronica E, Redeker S, Gorter JA. Expression and cellular dis-
tribution of major vault protein: a putative marker for pharmacoresistance
in a rat model for temporal lobe epilepsy. Epilepsia 2004; 45: 1506–16.
Volk HA, Lo ¨scher W. Multidrug resistance in epilepsy: rats with drug-
resistant seizures exhibit enhanced brain expression of P-glycoprotein
compared with rats with drug-responsive seizures. Brain 2005; 128:
Volk HA, Burkhardt K, Potschka H, Chen J, Becker A, Lo ¨scher W. Neuronal
expression of the drug efflux transporter P-glycoprotein in the rat hippo-
campus after limbic seizures. Neuroscience 2004; 123: 751–9.
with pharmaco-resistant temporal lobe epilepsy. Epilepsy Res 1998; 32:
Vreugdenhil M, Wadman WJ. Modulation of sodium currents in rat CA1
neurons by carbamazepine and valproate after kindling epileptogenesis.
Epilepsia 1999; 40: 1512–22.
Wang SJ, Huang CC, Hsu KS, Tsai JJ, Gean PW. Inhibition of N-type calcium
currents by lamotrigine in rat amygdalar neurones. Neuroreport 1996; 7:
antiepileptic drugs with human P-glycoprotein in vitro. J Pharmacol Exp
Ther 2003; 307: 262–7.
Whitaker WR, Faull RL, Dragunow M, Mee EW, Emson PC, Clare JJ.
Changes in the mRNAs encoding voltage-gated sodium channel types
II and III in human epileptic hippocampus. Neuroscience 2001; 106:
White HS, Brown SD, Woodhead JH, Skeen GA, Wolf HH. Topiramate
enhances GABA-mediated chloride flux and GABA-evoked chloride
currents in murine brain neurons and increases seizure threshold. Epilepsy
Res 1997; 28: 167–79.
White HS, Harmsworth WL, Sofia RD, Wolf HH. Felbamate modulates
the strychnine-insensitive glycine receptor. Epilepsy Res 1995; 20: 41–8.
Willow M, Gonoi T, Catterall WA. Voltage clamp analysis of the inhibitory
actions of diphenylhydantoin and carbamazepine on voltage-sensitive
sodium channels in neuroblastoma cells. Mol Pharmacol 1985; 27: 549–58.
Wozny C, Kivi A, Lehmann TN, Dehnicke C, Heinemann U, Behr J. Com-
ment on ‘On the origin of interictal activity in human temporal lobe
epilepsy in vitro’. Science 2003; 301: 463.
Wu Y, Wang W, Richerson GB. Vigabatrin induces tonic inhibition via
GABA transporter reversal without increasing vesicular GABA release.
J Neurophysiol 2003; 89: 2021–34.
Xie X, Dale TJ, John VH, Cater HL, Peakman TC, Clare JJ. Electrophysiolo-
gical and pharmacological properties of the human brain type IIA Na+
channel expressed in a stable mammalian cell line. Pflugers Arch 2001; 441:
Xie X, Lancaster B, Peakman T, Garthwaite J. Interaction of the antiepileptic
drug lamotrigine with recombinant rat brain type IIA Na+ channels and
withnativeNa+channelsinrathippocampalneurones. Pflugers Arch1995;
Yaari Y, Hamon B, Lux HD. Development of two types of calcium
channels in cultured mammalian hippocampal neurons. Science 1987;
Yue C, Yaari Y. KCNQ/M channels control spike after depolarization and
burst generation in hippocampal neurons. J Neurosci 2004; 24: 4614–24.
Zhang L, Ong WY, Lee T. Induction of P-glycoprotein expression in
astrocytes following intracerebroventricular kainate injections. Exp Brain
Res 1999; 126: 509–16.
Zhang X, Velumian AA, Jones OT, Carlen PL. Modulation of high-voltage-
activated calciumchannels in dentate granule cellsby topiramate.Epilepsia
2000; 41 Suppl 1: S52–60.
Zona C, Avoli M. Effects induced by the antiepileptic drug valproic acid upon
the ionic currents recorded in rat neocortical neurons in cell culture. Exp
Brain Res 1990; 81: 313–17.
Zona C, Avoli M. Lamotrigine reduces voltage-gated sodium currents in rat
central neurons in culture. Epilepsia 1997; 38: 522–5.
Zona C, Ciotti MT, Avoli M. Topiramate attenuates voltage-gated
sodium currents in rat cerebellar granule cells. Neurosci Lett 1997; 231:
Zona C, Niespodziany I, Marchetti C, Klitgaard H, Bernardi G, Margineanu
DG. Levetiracetam does not modulate neuronal voltage-gated Na+ and
T-type Ca2+ currents. Seizure 2001; 10: 279–86.
lamotrigine. Epilepsia 2002; 43: 685–90.
Page 18 of 18Brain (2005)S. Remy and H. Beck